Home Newsfeeds GE Gas Power Awarded $4.2M In Funding From ARPA-E To Develop Decarbonization Technologies

GE Gas Power Awarded $4.2M In Funding From ARPA-E To Develop Decarbonization Technologies

https://www.ge.com/news/press-releases/ge-gas-power-awarded-42-million-in-funding-from-arpa-e-to-develop-breakthrough

byBenzinga Newsdesk

July 28, 2022

1 minute read

https://www.ge.com/news/press-releases/ge-gas-power-awarded-42-million-in-funding-from-arpa-e-to-develop-breakthrough

News

EBET, Inc. Announces Corporate Restructuring And Profitability Plan

By Bill Haddad

August 15, 9:02 AM

Earnings Call Scheduled Today at 4:30 PM EDT to Detail 3rd Quarter Results of Corporate Restructuring, Revenue of $18.2 Million and Gross Profit of $7.2 Million LAS VEGAS, Aug. 15, 2022 /PRNewswire/ -- EBET,

EBET

SVB Leerink Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $315

By Benzinga Newsdesk

December 20, 8:02 AM

SVB Leerink analyst Mike Kratky maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target from $145 to $315.

MDGL

Media
News

What’s Going On With Affirm Stock Thursday?

By Anusuya Lahiri

June 20, 12:26 PM

Affirm stock gained over 85% in the last 12 months. Investors can gain exposure to the stock via Vanguard Small-Cap ETF and Vanguard Total Stock Market ETF.

AAPL

Credit Suisse Initiates Coverage On Adaptive Biotechnologies with Underperform Rating, Announces Price Target of $8

By Benzinga Newsdesk

August 25, 9:37 AM

Credit Suisse analyst Dan Leonard initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Underperform rating and announces Price Target of $8.

ADPT

GE Gas Power Awarded $4.2M In Funding From ARPA-E To Develop Decarbonization Technologies

Related Posts

EBET, Inc. Announces Corporate Restructuring And Profitability Plan

SVB Leerink Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $315

What’s Going On With Affirm Stock Thursday?

Credit Suisse Initiates Coverage On Adaptive Biotechnologies with Underperform Rating, Announces Price Target of $8